Advancing Practice Management: Integrating Immuno-Oncology Therapy for Advanced Non-Melanoma Skin Cancer

This four-part roundtable series with Oliver Wisco, DO; Jason Hawkes, MD, MS; Todd Schlesinger, MD; and George Murakawa, MD, PhD, provides a comprehensive look at the evolving role of immuno-oncology (IO) therapy in the management of advanced basal cell carcinoma (aBCC) and advanced cutaneous squamous cell carcinoma (aCSCC). The series begins with an overview of aBCC and aCSCC and their respective current treatment landscapes, with an emphasis on IO clinical trial data. It then explores patient selection criteria and decision-making for IO therapy, followed by real-world case studies illustrating diagnosis, treatment, and monitoring. Finally, the series addresses the operational and multidisciplinary considerations essential for implementing IO therapy effectively in clinical practice.

Part 1: The Role of IO Therapy in ​Advanced Non-Melanoma Skin Cancer

This roundtable video provides a comprehensive overview of aBCC and aCSCC. Experts discuss the current clinical treatment landscape, with a special focus on IO therapies. The session reviews key clinical trial data supporting IO therapy, highlighting its role in improving outcomes for patients with advanced disease.

Part 2: Identifying The Appropriate Patient for IO Therapy in Advanced Non-Melanoma Skin Cancer

In this segment, expert faculty explore the clinical considerations involved in selecting patients with aBCC and aCSCC for IO therapy. Topics include evaluation criteria, comorbidities, patient characteristics, and the shared decision-making process between clinicians and patients when determining the suitability of IO therapy.

Part 3: Real-World Case Studies and Insights on IO Therapy for Advanced Non-Melanoma Skin Cancer

This video presents real-world patient cases from each of the three expert speakers, illustrating the practical use of IO therapy in treating aBCC and aCSCC. Each case highlights key factors influencing therapy decisions, from diagnosis through treatment and post-treatment monitoring, providing valuable insights into individualized patient management.

Part 4: Operational and Logistical Considerations With IO Therapy for Advanced Non-Melanoma Skin Cancer

In this final roundtable segment, speakers discuss the operational and logistical aspects of delivering IO therapy for patients with aBCC and aCSCC. The session includes guidance on infusion processes, monitoring protocols, and the importance of multidisciplinary collaboration to ensure coordinated care throughout the treatment journey.